A week before the ASRS meeting, Regeneron, which markets aflibercept (Eylea), announced a $200 million matching-donation ...

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

The FDA issued a Complete Response Letter for Regeneron’s biologics license application for odronextamab, a bispecific antibody targeting CD20 and CD3 for the treatment of relapsed or refractory ...

Cisco today announced it will host Splunk's annual .conf25 user conference from September 8–11, 2025, at the Thomas Michael ...

The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by ...

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

The First Trust Health Care AlphaDEX ETF (FXH) was launched on May 8, 2007, and is a passively managed exchange traded fund ...